Bronchodilator Efficacy of Combined Salmeterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

A. Baloira Villar and C. Vilariño Pombo
Sección de Neumología, Complexo Hospitalario de Pontevedra, Mourente, Pontevedra, Spain.

OBJECTIVE: Bronchodilators are still the most effective drugs for controlling the symptoms of chronic obstructive pulmonary disease (COPD). Tiotropium bromide, a long-acting anticholinergic drug, has recently been added to the therapeutic arsenal for the disease. To date, there have been no studies combining 2 long-acting bronchodilators. The aim of the present trial was to determine whether the combination of salmeterol and tiotropium improved lung function in COPD patients more than either of them alone.

PATIENTS AND METHODS: Twenty-two patients (20 men) diagnosed with COPD, with a mean age of 64 years, were enrolled in this cross-over trial. Active smokers were excluded. Mean (SD) forced expiratory volume in 1 second (FEV₁) was 43% (14%) of predicted. All patients were experienced in the use of inhalers. The following 3 therapeutic combinations were randomly assigned to be administered for a 1-week period: 

a) fluticasone (500 µg/12 h), salmeterol (50 µg/12 h) and placebo; 
b) fluticasone, tiotropium (18 µg/24 h), and placebo; and 
c) fluticasone, salmeterol, and tiotropium. 

At the end of each period, forced spirometry was performed before inhalation of the therapeutic combination (between 8:30 AM and 9:30 AM) and 2 hours after inhalation. Throughout the week, morning peak flow rates measured immediately before inhalation were recorded, and there was a 48-hour wash-out period between each therapeutic combination.

RESULTS: All the patients completed the protocol. There were no significant differences in preinhalation or postinhalation FEV₁, with salmeterol compared to tiotropium (preinhalation FEV₁, 1.17 [0.55] L compared to 1.19 [0.49] L; postinhalation FEV₁, 1.32 [0.65] L compared to 1.29 [0.61] L). In all cases postinhalation FEV₁ was significantly higher than preinhalation FEV₁. The combination of fluticasone, salmeterol, and tiotropium proved superior to the other 2 combinations with respect to both preinhalation FEV₁ and postinhalation FEV₁ (preinhalation FEV₁, 1.32 [0.56] L [P<0.03 in both comparisons]; postinhalation FEV₁, 1.49 [0.68] L [P<0.001 in both comparisons]). Peak flow rate was also significantly higher with the combination of the 2 bronchodilators (345 L/min compared to 291 L/min and 311 mL, respectively [P<0.04 in both cases]). There were no notable side effects.

CONCLUSIONS: In terms of improvement in lung function, the combination of salmeterol and tiotropium together with fluticasone is more effective in patients with moderate-to-severe COPD than either of the 2 bronchodilators administered alone.

Key words: Chronic obstructive pulmonary disease (COPD). Salmeterol. Tiotropium. Spirometry.

Eficacia broncodilatadora de la asociación de salmeterol y tiotropio en pacientes con EPOC

OBJETIVO: Los broncodilatadores continúan siendo los fármacos más eficaces para el control de los síntomas de la enfermedad pulmonar obstructiva crónica (EPOC). Recientemente se ha añadido un anticolinérgico de acción larga, el bromuro de tiotropio, al arsenal terapéutico de esta enfermedad. No existen estudios que hayan asociado 2 broncodilatadores de acción sostenida. El objetivo de este estudio ha sido comprobar si la asociación de salmeterol y tiotropio a pacientes con EPOC mejora la función pulmonar respecto a cuando se administran aislados.

PACIENTES Y MÉTODOS: Se incluyó en el estudio a 22 pacientes diagnosticados de EPOC (20 varones), con una edad media de 64 años. Se excluyó a los fumadores activos. El volumen espiratorio forzado en el primer segundo (FEV₁) medio ± desviación estándar fue un 43 ± 14% del teórico. Todos los pacientes tenían amplia experiencia en el uso de los dispositivos de inhalación. Se realizaron 3 combinaciones terapéuticas de forma aleatoria durante una semana: 
a) fluticasone (500 µg/12 h), salmeterol (50 µg/12 h) y placebo; 
b) fluticasone, tiotropium (18 µg/24 h) y placebo; y 
c) fluticasone, salmeterol y tiotropio. Se informó del pico de flujo matutino de la mañana antes de la inhalación de la combinación y 2 h después de ésta. Durante toda la semana se recogió el pico de flujo matutino inmediatamente antes de la inhalación de los fármacos, dejando 48 h de lavado entre cada asociación.

RESULTADOS: Todos los pacientes finalizaron el protocolo. No hubo diferencias significativas en el FEV₁ tanto valle como postinhalación con salmeterol y tiotropio (FEV₁ valle: 1,17 ± 0,55 frente a 1,19 ± 0,49 l; FEV₁ postinhalación: 1,32 ± 0,65 frente a 1,29 ± 0,61 l). En todos los casos el FEV₁ postinhalación fue significativamente superior al FEV₁ valle. La combinación de fluticasone, salmeterol y tiotropio se mostró superior a las otras 2 tanto en el FEV₁ valle como postinhalación (FEV₁ valle: 1,32 ± 0,26 l, p < 0,03 en ambos casos; FEV₁ postinhalación: 1,49 ± 0,68 l, p < 0,001 en los 2 casos). El pico de flujo también fue significativamente mayor con la combinación de los 2 broncodilatadores (345 frente a 291 l/m y 311 l/m, respectivamente; p < 0,04 en ambos casos). No hubo efectos secundarios reseñables.

CONCLUSIONES: La asociación de salmeterol y tiotropio unidos a fluticasone en pacientes con EPOC de grado moderado-grave es más eficaz en términos de mejora funcional respiratoria que cualquiera de los 2 broncodilatadores dados de forma aislada.

Introduction

Chronic obstructive pulmonary disease (COPD) affects 9% of the adult population1 and the incidence is expected to continue to increase, possibly making it the third cause of death in the western world by 2020.2 The principal aim of treatment is to relieve symptoms and reduce the number of exacerbations. The use of bronchodilators is the most effective way to achieve symptomatic improvement.3 The role of inhaled corticosteroids is still controversial.4-6 While a promising study of the phosphodiesterase-4 inhibitor cilomilast7 has recently been published, its clinical use seems improbable in the short term and bronchodilators, chiefly anticholinergics and β2-agonists, remain the treatments of choice. To evaluate the efficacy of treatment, new parameters, such as the results of quality of life questionnaires, dyspnea scales, and stress tests, have been introduced. However, forced spirometry is still one of the most important tests in the monitoring of COPD patients. The first sustained-action bronchodilators were long-acting β2-agonists, which have now been on the market for several years. Several clinical trials have shown these drugs to be more effective than placebo8,9 or ipratropium10 in improving lung function, quality of life, and stress tolerance. Recently a new bronchodilator was introduced: tiotropium, an anticholinergic whose characteristics make it a first-line drug in the therapeutic arsenal. Several trials have demonstrated its efficacy compared to both placebo and ipratropium,11,12 and it has even been shown to be superior to salmeterol.13 A trial that showed the superiority of the combination of fluticasone and salmeterol over either drug administered separately14 was recently published, as was another that showed budesonide and formoterol to be superior to budesonide alone.15 However, we know of no other study combining a long-acting β2-agonist and tiotropium, which would appear a priori to be the most reasonable combination in patients with severe COPD.

In order to determine the bronchodilating efficacy of this combination we designed a preliminary trial in which we compared the combined use of salmeterol and tiotropium with each drug administered separately in patients with moderate-to-severe COPD.

Patients and Methods

Patients

Twenty-two patients diagnosed with COPD—forced expiratory volume in 1 second (FEV₁) less than 70% and the ratio of FEV₁ to forced vital capacity (FVC) less than 0.70—and followed in our department were invited to participate in the trial. All patients had been using an inhaled corticosteroid and a long-acting β2-agonist as controller medication and ipratropium as rescue medication. This treatment had remained stable for at least 3 months prior to the trial. A minimum of 3 months without exacerbation was required for inclusion. None of the patients were active smokers and all received training in the use of the new inhalers in our department. In all cases the improvement in FEV₁ after 1000 µg of terbutaline was less than 15%. The role of inhaled corticosteroids is still controversial.4-6 While a promising study of the phosphodiesterase-4 inhibitor cilomilast7 has recently been published, its clinical use seems improbable in the short term and bronchodilators, chiefly anticholinergics and β2-agonists, remain the treatments of choice. To evaluate the efficacy of treatment, new parameters, such as the results of quality of life questionnaires, dyspnea scales, and stress tests, have been introduced. However, forced spirometry is still one of the most important tests in the monitoring of COPD patients. The first sustained-action bronchodilators were long-acting β2-agonists, which have now been on the market for several years. Several clinical trials have shown these drugs to be more effective than placebo8,9 or ipratropium10 in improving lung function, quality of life, and stress tolerance. Recently a new bronchodilator was introduced: tiotropium, an anticholinergic whose characteristics make it a first-line drug in the therapeutic arsenal. Several trials have demonstrated its efficacy compared to both placebo and ipratropium,11,12 and it has even been shown to be superior to salmeterol.13 A trial that showed the superiority of the combination of fluticasone and salmeterol over either drug administered separately14 was recently published, as was another that showed budesonide and formoterol to be superior to budesonide alone.15 However, we know of no other study combining a long-acting β2-agonist and tiotropium, which would appear a priori to be the most reasonable combination in patients with severe COPD.

In order to determine the bronchodilating efficacy of this combination we designed a preliminary trial in which we compared the combined use of salmeterol and tiotropium with each drug administered separately in patients with moderate-to-severe COPD.

Patients and Methods

Patients

Twenty-two patients diagnosed with COPD—forced expiratory volume in 1 second (FEV₁) less than 70% and the ratio of FEV₁ to forced vital capacity (FVC) less than 0.70—and followed in our department were invited to participate in the trial. All patients had been using an inhaled corticosteroid and a long-acting β2-agonist as controller medication and ipratropium as rescue medication. This treatment had remained stable for at least 3 months prior to the trial. A minimum of 3 months without exacerbation was required for inclusion. None of the patients were active smokers and all
The highest and lowest values were excluded from the analysis, and the 5 central values were chosen. All values were expressed as means (SD). For comparisons of FEV\textsubscript{1}, both absolute and percent of predicted values were used. The latter appear to be more significant in patients with moderate-to-severe COPD. For samples with normal distributions, analysis of variance was carried out and then the Bonferroni multiple comparison test applied; for non-normal distributions, the Wilcoxon test was used. A $P$ value less than .05 was considered significant.

Results

All 22 patients completed the protocol and all treatments were well tolerated. Only 2 of the patients, whose characteristics are shown in Table 1, were women. Active smokers were excluded from the study. The mean (SD) basal FEV\textsubscript{1} was 1.16 (0.56) L (43% [14%] of predicted) and mean peak flow rate was 274 L/m. Postinhalation FEV\textsubscript{1} was significantly higher than preinhalation FEV\textsubscript{1} in all cases. An improvement greater than 10% was achieved in approximately half the patients, with no notable differences between the 3 treatments (Table 2). There were no significant differences from basal FEV\textsubscript{1} or in the peak flow rate after treatment with either the fluticasone plus salmeterol or the fluticasone plus tiotropium combination. The combination of salmeterol plus tiotropium (Table 3) was superior to either of the 2 bronchodilators administered alone for both preinhalation and postinhalation FEV\textsubscript{1}, as can be seen in Figure 1 and Figure 2 ($P$<.03 in all cases). The peak flow rate was also significantly better with the combination of the 2 bronchodilators (345 [179] compared to 291 [126] L/m with salmeterol and 311 [151] L/m with tiotropium; in both cases, $P$<.04). There were no differences in the results achieved with salmeterol and those achieved with tiotropium (Figure

**TABLE 1**

**Patient Characteristics**

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>64 (range: 49-77)</td>
</tr>
<tr>
<td>Sex, M/W</td>
<td>20/2</td>
</tr>
<tr>
<td>FVC, L</td>
<td>2.69 (1.03)</td>
</tr>
<tr>
<td>FEV\textsubscript{1}, L</td>
<td>1.16 (0.56)</td>
</tr>
<tr>
<td>FEV\textsubscript{1}, % of predicted</td>
<td>43 (14)</td>
</tr>
<tr>
<td>FEV\textsubscript{1}/FVC</td>
<td>43% (11%)</td>
</tr>
<tr>
<td>Peak flow rate, L/m</td>
<td>274 (108)</td>
</tr>
</tbody>
</table>

*Data are expressed as means (SD) or range. M indicates men; W, women; FVC, forced vital capacity; FEV\textsubscript{1}, forced expiratory volume in 1 second.

**TABLE 2**

**Forced Expiratory Volume in 1 Second Preinhalation and 2 Hours Following Inhalation of the Various Combinations**

<table>
<thead>
<tr>
<th>Combination</th>
<th>Preinhalation FEV\textsubscript{1}, L</th>
<th>Postinhalation FEV\textsubscript{1}, L</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLU+SAL</td>
<td>1.17 (0.55)</td>
<td>1.32 (0.65)</td>
</tr>
<tr>
<td>FLU+TIO</td>
<td>1.19 (0.49)</td>
<td>1.29 (0.61)</td>
</tr>
<tr>
<td>FLU+SAL+TIO</td>
<td>1.32 (0.56)</td>
<td>1.49 (0.68)</td>
</tr>
</tbody>
</table>

*Data are expressed as means (SD). FEV\textsubscript{1} indicates forced expiratory volume in 1 second. FLU, fluticasone; SAL, salmeterol; TIO, tiotropium.

In all cases, postinhalation FEV\textsubscript{1} was significantly higher than preinhalation FEV\textsubscript{1}.
tiotropium’s long-term effect on lung function loss in COPD patients. To date, we know of no study combining a long-acting \( \beta_2 \)-agonist and tiotropium. The available evidence suggests that such a combination would be the treatment of choice in cases of severe disease, given that \( \beta_2 \)-agonists and anticholinergics have different mechanisms of action and that both exhibit prolonged binding to their respective receptors, thus allowing sustained bronchodilation.

In evaluating the efficacy of a drug for the treatment of COPD, there are several possible objects of study: global improvement in quality of life, decrease in the number of exacerbations, increase in life expectancy, and functional improvement. Quality of life is not directly proportional to lung function variables, especially FEV\(_1\), but in general patients shown by spirometry to have greater airway obstruction have a worse score on quality of life questionnaires, more exacerbations, and, especially in severe COPD, shorter life expectancy. It has long been established that the reversibility of airway obstruction has implications for prognosis.\(^{18}\) The St. George’s Respiratory Questionnaire, one of the most widely-used instruments for assessing health-related quality of life, shows good correlation with FEV\(_1\).\(^{19}\) Achieving significant improvements in FEV\(_1\) would seem, therefore, to be a reasonable therapeutic objective. The present study clearly supports the use of salmeterol and tiotropium in moderate-to-severe COPD patients. Some of our data are particularly significant and worthy of special note. In all cases postinhalation FEV\(_1\) was significantly higher than preinhalation values, although in the case of tiotropium, the mean improvement (approximately 8%) did not reach clinical significance. Although there was considerable variation among patients, the number of those who achieved clinically significant bronchodilation with each treatment was quite similar (11 patients with salmeterol, 9 with tiotropium, and 12 with the combination), and in a larger sample the similarity might be even greater. Another noteworthy finding was that there were no differences between salmeterol and tiotropium with respect to preinhalation and postinhalation FEV\(_1\). This somewhat contradicts the results obtained by Donohue et al.,\(^{13}\) who found all spirometric variables to be consistently superior with tiotropium treatment, which was also associated with improved quality of life. Such differences cannot be attributed to the severity of functional impairment, as this was similar in the 2 studies (FEV\(_1\) of 40% [12%] of predicted compared to 43% [14%]).

### Table 3

<table>
<thead>
<tr>
<th>Combinations</th>
<th>Preinhalation FEV(_1) L</th>
<th>Postinhalation FEV(_1) L</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLU+TIO compared to FLU+SAL</td>
<td>1.17 (0.55) compared to 1.19 (0.49) (NS)</td>
<td>1.32 (0.65) compared to 1.29 (0.61) (NS)</td>
</tr>
<tr>
<td>FLU+SAL+TIO compared to FLU+SAL</td>
<td>1.32 (0.56) compared to 1.17 (0.55) ((P&lt;.023))</td>
<td>1.49 (0.68) compared to 1.32 (0.65) ((P&lt;.001))</td>
</tr>
<tr>
<td>FLU+SAL+TIO compared to FLU+TIO</td>
<td>1.32 (0.56) compared to 1.19 (0.49) ((P&lt;.014))</td>
<td>1.49 (0.68) compared to 1.29 (0.61) ((P&lt;.001))</td>
</tr>
</tbody>
</table>

\(^{*}\)Data are expressed as means (SD). FEV\(_1\) indicates forced expiratory volume in 1 second; FLU, fluticasone; SAL, salmeterol; TIO, tiotropium; NS, not significant.

There were no significant differences in preinhalation or postinhalation FEV\(_1\) with the combinations of FLU+SAL or FLU+TIO. The combination of FLU+SAL+TIO was significantly superior in both cases.

**Figure 3.** Peak flow rate values are expressed as the mean of the 5 central values (see text). In this case as well, the combination of bronchodilators was shown to be superior, although not as significantly as in the case of FEV\(_1\). SAL indicates salmeterol; TIO, tiotropium. \(^{*}\)\(P<.04\).
Morning peak flow measurements are of limited value in monitoring COPD. Nevertheless, we believed the inclusion of such information in a functional study such as ours to be of interest. Morning peak flow behaved similarly to FEV1: no significant differences were found between salmeterol and tiotropium, but peak flow was clearly superior when the 2 drugs were combined, although the statistical significance of the difference was less than that observed for FEV1.

It is unusual nowadays for the treatment of patients with severe COPD not to include inhaled corticosteroids. These drugs partially compensate for the loss of efficacy of prolonged \( \beta_2 \)-agonist use. Thus, we decided to include fluticasone in all the combinations in order to bring the treatments closer to real clinical practice.

The present preliminary trial has several limitations. First, obviously, is the size of the sample. While the inclusion of a greater number of patients might have altered the results, substantial variation in the data is unlikely, and even smaller numbers of patients have been used in other studies of bronchodilation.20,21 In order to minimize the problem, we chose patients who were familiar with correct spirometry technique and with the objectives of the study. All the tests were performed by the same nurse, who had considerable experience in lung-function testing. We consider the present study to be a preliminary one because it dealt only with lung function variables, but we believe the results support the design of another more ambitious project that would allow us to determine the long-term impact of a combination of a long-acting \( \beta_2 \)-agonist and tiotropium on quality of life, exacerbations, and lung function loss.

In conclusion, the present study showed combined salmeterol and tiotropium to have a greater bronchodilating effect in patients with moderate-to-severe COPD than either drug administered separately. This opens the door to the use of such a combination in clinical practice for such patients.

Acknowledgments

This study would not have been possible without the invaluable cooperation of Mercedes Garalt of the lung function testing laboratory.

REFERENCES